Muscarinic acetylcholine receptors (mAChRs) are central to the modulation of neurotransmission in the human brain and are emerging as promising targets in the management of neuropsychiatric disorders.

In the December 2 Nature Chemical Biology, researchers led by Jeffrey Conn at Vanderbilt University, Nashville, Tennessee, report that they have developed a small molecule that not only boosts the ...

Research at Monash University has led to the identification of structurally novel muscarinic acetylcholine receptor (mAChR) positive allosteric modulators (PAMs) with potential utility in treating ...

Acetylcholine is a chemical messenger, or neurotransmitter, that plays an important role in brain and muscle function. Imbalances in acetylcholine are linked with chronic conditions, such as Alzheimer ...

The fine balance between potency and selectivity that looms large in drug development has long stymied efforts to target the M1 muscarinic acetylcholine receptor (mAChR) for treatment of Alzheimer ...

BOSTON--(BUSINESS WIRE)--Karuna Pharmaceuticals, focused on targeting muscarinic receptors for the treatment of central nervous system (CNS) disorders including schizophrenia and Alzheimer’s Disease ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

11C-Methionine positron emission tomography as an early predictor of outcome in bone and soft tissue sarcomas treated by carbon ion radiotherapy No significant financial relationships to disclose.

More than 60% of complement inhibitor–naive patients with acetylcholine receptor–positive generalized myasthenia gravis (MG) in diverse clinical populations had a clinically meaningful reduction in MG ...

In recent years, nootropics, also called smart drugs, have gained popularity among people looking to improve their mental performance. Acetylcholine is a neurotransmitter, or brain chemical, that ...

ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in ...